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B-1a cells constitutively secrete natural antibody that provides immediate protection
against microbial pathogens and functions homeostatically to speed removal of apoptotic
cell debris. Although B-1a cells are especially prominent in the peritoneal and pleural cav-
ities, some B-1a cells reside in the spleen. A small subset of splenic B-1a cells in naïve,
unimmunized mice express CD138, a recognized plasma cell antigen, whereas the bulk of
splenic B-1a cells are CD138 negative. Splenic B-1a cells in toto have been shown to gen-
erate much more antibody per cell than peritoneal B-1a cells; however, specific functional
information regarding CD138+ splenic B-1a cells has been lacking. Here, we find a higher
proportion of CD138+ splenic B-1a cells spontaneously secrete more IgM as compared
to CD138− B-1a cells. Moreover, IgM secreted by CD138+ splenic B-1a cells is skewed
with respect to N-region addition, and some aspects of VH and JH utilization, as compared
to CD138− splenic B-1a cells and peritoneal B-1a cells. The small population of CD138+
splenic B-1a cells is likely responsible for a substantial portion of natural IgM and differs
from IgM produced by other B-1a cell subsets.
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INTRODUCTION
Murine B-1a cells represent a unique lymphocyte lineage distin-
guished by specific ontologic, phenotypic, and functional char-
acteristics (1, 2). Although the human equivalent of mouse B-1a
cells has been described recently (3, 4), most knowledge about B-
1a cells has been generated from studies in mice. It has been shown
that B-1a cells spontaneously and constitutively generate “natural”
immunoglobulin (Ig), which constitutes the vast majority of rest-
ing serum IgM and about half of resting IgA (5). The natural Ig
produced by B-1a cells differs from Ig produced by B-2 cells. B-
1a cell Ig contains minimal N-region addition and little somatic
hypermutation (6–9). As a result,B-1a cell Ig tends to be“germline-
like”; that is, to accurately reflect germline sequences without the
intervention of randomly added nucleotides or mutated residues.
Because B-1a cell Ig reflects germline coding, the B-1a cell reper-
toire is to a large extent inherited. Therefore, those sequences that
enhance an organism’s survival to reproductive age are likely to be
retained.
B-1a cell Ig is both polyreactive and autoreactive. Polyreac-
tive natural Ig is always present and acts as an initial shield
against many common infectious agents, particularly during the
lag period that precedes the development of adaptive, high affinity
antigen-specific antibody produced by germinal center B-2 cells
(10–15). Autoreactive natural Ig has been implicated in the dispo-
sition of irreversibly damaged cells and noxious molecular debris
and in so doing maintains homeostasis and prevents untoward
inflammation (16).
B-1a cells are preferentially located at serosal surfaces, most
prominently in the peritoneal cavity. However, B-1a cells are also
located in the spleen, and splenic B-1a cells differ from peritoneal
B-1a cells in a number of characteristics, including the intensity of
Ig secretion (17–19). Through the unique property of self-renewal
(20), mature B-1a cells can give rise to their own progeny in place,
which suggests differentiation and migration in adult animals is
minimal. Therefore, B-1a cells were considered for a time to rep-
resent static, Ig generating lymphocytes. However, recent reports
suggest a richer life experience. Peritoneal B-1a cells may respond
to specific and/or non-specific stimulation, migrate to the spleen,
and may then return to the peritoneal cavity as memory B-1a cells
(21–23). Further, a subset of splenic B-1a cells expresses CD138
(24) suggesting that appropriately stimulated B-1a cells may take a
different path and differentiate in a plasma cell direction. CD138+
B-1a cells differ from CD138+ plasma cells in retaining B-1a-
specific surface antigen expression. Identification of splenic B-1a
cells that express CD138 raises the question of whether CD138+
B-1a cells differ from CD138− B-1a cells, or whether these splenic
B-1a cell populations behave similarly, especially with respect to
the amount of Ig secretion.
MATERIALS AND METHODS
MICE
Male BALB/c-ByJ mice of 6–8 weeks age were obtained from
the Jackson Laboratory. Mice were cared for and handled in
accordance with National Institutes of Health and institutional
guidelines.
CELL PURIFICATION AND FLOW CYTOMETRY
Splenocytes were obtained from 8 to 14-week-old BALB/c-
ByJ male mice and stained with fluorescence-labeled antibodies
to B220, CD5, CD23, and CD138. Splenic B cell populations
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were sort-purified (BD Biosciences Influx) as follows: splenic
B-2 cells, B220hiCD5−CD23hiCD138−; splenic CD138+ B-1a
cells, B220loCD5loCD23−CD138+; splenic CD138− B-1a cells,
B220loCD5loCD23−CD138−. Post-sort analysis of the splenic B-
1a and B-2 cell populations showed each to be ≥98% pure.
The following rat anti-mouse antibodies were obtained from BD
Biosciences: FITC-conjugated B220 (clone RA3–6B2), PE-Cy5-
conjugated CD5 (clone 53–7.3), PE-conjugated CD138 (clone
281–2). The anti-mouse Pacific Blue-conjugated CD23 antibody
(clone B3B4) was obtained from BioLegend.
ELISPOT ASSAY
ELISPOT assay was carried out as previously described (25).
In brief, sort-purified, naive B cells were distributed onto
MultiScreen*-IP Plates (Millipore) pre-coated with goat anti-
mouse Ig (H+ L) and then incubated in RPMI 1640 contain-
ing 10% heat-inactivated fetal bovine serum, 2 mM l-glutamine,
50µM 2-mercaptoethanol, 100 U/ml penicillin, and 100µg/ml
streptomycin for 4 h at 37°C and 5% CO2. Plates were treated with
alkaline phosphatase-conjugated goat anti-mouse IgM (South-
ern Biotechnology Associates) and developed with 5-bromo-
4-chloro-3-indolyl phosphate/p-NBT chloride substrate (KPL).
IgM-secreting B cells were enumerated using Phoretix Expression
software (Non-Linear Dynamics).
SINGLE CELL SEQUENCING AND ANALYSIS
Splenic CD138+ B-1a and CD138− B-1a cells were sorted onto
48-well AmpliGrid slides (Advalytix). Reverse transcription and
PCR (Qiagen OneStep RT-PCR) were carried out as described
previously (8). The products were purified and then sequenced
(Genewiz) using the MsVHE primer. Sequences were then ana-
lyzed using an online sequence analysis tool for VDJ sequences
(IMGT, the international ImMunoGeneTics information system).
Each of the sequences analyzed and reported in this manuscript,
from each population, is characterized by a unique V, D, and J
segment along with a unique CDR3. Sequences with identical V,
D, and J segments as well as identical CDR3 regions were elimi-
nated from consideration according to the criteria of Kantor et al.
(26). CDR3 hydrophobicity was calculated using the online calcu-
lator GRAVY (http://www.gravy-calculator.de/index.php?page=
file). Sequences are provided as Data Sheet in Supplementary
Material.
RESULTS
We sort purified splenic B-1a cells to separate CD138+ and
CD138− populations using a variation on the gating strategy
reported by Herzenberg and colleagues (24). The selected splenic
populations were gated as B220loCD5loCD23−CD138+ (CD138+
B-1a cells) and B220loCD5loCD23−CD138− (CD138− B-1a cells),
as depicted in Figure 1. Far fewer CD138+ B-1a cells were recov-
ered than CD138− B-1a cells with the former amounting to less
than 1/100 the number of the latter. We questioned whether
CD138 expression marks splenic B-1a cells that vigorously secrete
Ig, as it does B-2 plasma cells. To address this, we tested IgM
secretion of sorted splenic B-1a cells from naïve, unimmunized
BALB/c-ByJ mice by ELISPOT assay. We found both CD138+ and
CD138− B-1a cells secreted IgM spontaneously, without stimula-
tion, over a 4 h period. However, the frequency of IgM-secreting
B-1a cells was significantly higher for CD138+ B-1a cells in com-
parison to CD138− B-1a cells, as illustrated in Figure 2A and
enumerated in Figure 2B. More than half of CD138+ splenic B-
1a cells (56%) spontaneously secreted IgM whereas the fraction of
CD138− splenic B-1a cells that secreted IgM (5%) was much lower.
Beyond frequency, the amount of IgM secreted by CD138+ splenic
FIGURE 1 | Gating strategy for CD138+ and CD138− splenic B-1a cells in naïve non-immune mice. Single cell suspensions of RBC lysed spleens from
BALB/c-ByJ mice were prepared and stained with B220-FITC, CD5-PE-Cy5, CD23-Pacific Blue, and CD138-PE. Splenic CD138+ and CD138− B-1a cells were
gated as shown and sorted.
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FIGURE 2 | CD138+ and CD138− splenic B-1a cell IgM secretion in naïve
non-immune mice. Sorted splenic CD138+ and CD138− B-1a cells were
evaluated for IgM secretion by ELISPOT. Cells were placed on the ELISPOT
membrane for 4 h. (A) Representative experiment showing 10,000 or 150
CD138− cells total placed per well as compared to 150 CD138+ cells total
per well. (B)The spots were enumerated to determine mean spot area
(black) and the percent of cells secreting IgM (gray). Results shown
represent mean values of three independent experiments with lines
indicating standard errors of the means.
B-1a cells was significantly greater than that of CD138− splenic B-
1a cells, as judged by relative mean spot area (Figure 2B). CD138+
B-1a cells generated ELISPOTS that were more than six times as
large as the ELISPOTS produced by CD138− B-1a cells. Still, both
CD138+ and CD138− splenic B-1a cells secreted more IgM per
cell than peritoneal B-1a cells (18).
We questioned whether IgM produced by CD138+ B-1a cells
represents a selected repertoire in comparison to CD138− B-1a
cells. To address this, we sorted single cell CD138+ and CD138−
splenic B-1a cells and analyzed individual antibodies by PCR
amplification and sequencing. We found overall similarity in
VH–DH–JH usage with several significant differences. Among VH
gene segments, VH3 was expressed significantly less frequently
by CD138+ splenic B-1a cells (3%; n= 77; Figure 3A) as com-
pared to CD138− splenic B-1a cells (16%; n= 92; Figure 3A)
(p= 0.003). CD138+ splenic B-1a cells also expressed VH3 less
frequently than peritoneal B-1a cells [13%; n= 56; Ref. (8)]
(p= 0.02). In contrast, VH5 was expressed more frequently by
CD138+ splenic B-1a cells (29%) as compared to CD138−
splenic B-1a cells (20%), although this difference did not reach
the level of significance. Among DH gene segments, DFL16.1
was expressed less frequently, and DSP was expressed more fre-
quently, by CD138+ splenic B-1a cells as compared to CD138−
splenic B-1a cells although these differences were not significant
(Figure 3C). Among JH gene segments, JH3 was expressed signifi-
cantly more frequently (42%; Figure 3B) (p= 0.005) and JH2 was
expressed significantly less frequently (18%; Figure 3B) (p= 0.03),
by CD138+ splenic B-1a cells as compared to CD138− splenic
FIGURE 3 |VH, DH, and JH analysis of CD138+ and CD138− splenic B-1a
cells. Immunoglobulins were amplified by PCR from single sorted splenic
CD138+ (n=77) and CD138− (n=92) B-1a cells and evaluated for (A) V, (B)
J, and (C) D segment heavy chain usage. The percent of cells (sequences)
expressing each segment is displayed. Chi square and Fisher’s exact tests
were used to determine significance.
B-1a cells (22 and 33%, respectively). The latter utilization of
JH3 and JH2 by CD138− splenic B-1a cells approximated that of
peritoneal B-1a cells [18 and 27%, respectively, Ref. (8)]. Thus,
distinctive V and J gene segment usage separated CD138+ splenic
B-1a cells from CD138− splenic B-1a cells and peritoneal B-1a
cells.
Much attention has focused on N-region addition in B-1a cell
Ig, which is typically severely limited in comparison to B-2 cell
Ig. We questioned whether CD138+ B-1a cell Ig represents a
selected subset of all B-1a cell Ig. To address this, we analyzed
N-addition at the D–J and V–D junctions and determined CDR3
length. Analyzing the junctions separately, we found the average
length of N-additions at the D–J junction of CD138+ splenic B-
1a cell antibodies was larger than that of CD138− splenic B-1a
cells (p= 0.03 by Mann–Whitney U ) (Table 1). This bespeaks
increased diversity among antibodies expressed by CD138+ B-
1a cells as compared to CD138− B-1a cells. However, there were
no significant differences between CD138+ and CD138− splenic
B-1 cell antibodies at V–D junction in terms of mean N-addition
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length. Regardless, overall N-addition in CD138+ splenic B-1a cell
Ig was significantly different (p= 0.003 by Chi square analysis)
from that of CD138− splenic B-1a cell Ig (Figure 4B), emphasiz-
ing that CD138 expression divides splenic B-1a cells into distinct
populations.
In previous work, we analyzed N-addition frequency of
Ig sequences amplified from peritoneal B-1a cells and from
splenic B-2 cells (8). Antibodies expressed by both CD138+
and CD138− splenic B-1a cells contained significantly more N-
additions (Figure 4A) in comparison to antibodies expressed by
Table 1 | Mean N-region addition and CDR3 lengths (±SD).
V–D D–J CDR3 length
CD138+ splenic B-1a 1.7 (±2.2) 1.8 (±1.9) 11.8 (±1.9)
CD138− splenic B-1a 2.3 (±2.8) 1.3 (±1.8) 11.6 (±2.6)
B-1a cells in the peritoneal cavity,by Chi square analysis (Figure 4B
and Ref. (8); p< 0.0001 and p= 0.02, respectively). Conversely,
antibodies expressed by both CD138+ and CD138− splenic B-1a
cells contained significantly fewer N-additions in comparison to
antibodies expressed by splenic B-2 cells, by Chi square analysis
(Figure 4B and Ref. (8); p= 0.0003 and p< 0.0001, respectively).
Thus, whereas Ig sequences from CD138+ and CD138− splenic
B-1a cells differ in N-addition, both populations of splenic B-1a
cells differ from peritoneal B-1a cells and splenic B-2 cells, whose
Ig contains less and more N-addition, respectively.
We further examined CDR3 length and found that despite dif-
ferences in N-addition between CD138+ and CD138− splenic
B-1a cells, average Ig CDR3 lengths were not significantly dif-
ferent for the two populations (Table 1; Figure 4C). Moreover,
average Ig CDR3 hydrophobicity indices were similar for CD138+
and CD138− splenic B-1a cell antibodies (−0.63± 0.065 and
−0.69± 0.064 SEM, respectively). Thus, the small CD138+ splenic
FIGURE 4 | N-region addition and CDR3 length analysis of CD138+ and
CD138− splenic B-1a cells. Immunoglobulins were amplified by PCR from
single sorted splenic CD138+ (n=77) and CD138− (n=92) B-1a cells and
evaluated for N-region additions and CDR3 lengths. (A)The number of
N-additions at each junction is shown. The graphs display the percent of
sequences with 0–10 N-additions at each junction for CD138+ (black bars)
and CD138− (gray bars) splenic B-1a cells. (B) N-addition analysis of the
V–D and D–J junctions together. (C) CDR3 length analysis of
immunoglobulin sequences from CD138+ (black bars) and CD138− (gray
bars) splenic B-1a cells.
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B-1a cell population expresses Ig that varies in Ig gene segment
usage and is more diverse on account of increased N-addition, as
compared to the dominant CD138− splenic B-1a cell population,
but differs little in CDR3 length and CDR3 hydrophobicity.
DISCUSSION
Our results further characterize CD138-bearing B-1a cells, first
identified by Yang et al. (24), which appear as a very small B cell
population in the spleen. A large fraction of this small popula-
tion secretes IgM, and an increased amount of IgM is secreted, in
comparison with CD138− splenic B-1a cells and peritoneal B-1a
cells. Thus, although their numbers may be small, it is likely that
CD138+ splenic B-1a cells make a substantial contribution to the
circulating pool of natural antibodies. Therefore, the nature of the
CD138+ antibody repertoire is of interest in understanding the
protective capacity of natural IgM.
The repertoire of these potently secreting CD138+ splenic B-
1a cells is somewhat skewed away from VH3 and JH2, and toward
JH3. This would seem to parallel the situation with the peritoneal
B-1a cell repertoire, in which overall usage of VH gene segments is
similar to that of B-2 cells except for the key difference of increased
VH11 and VH12 expression, the two VH families responsible for
PtC binding (27–29). In other words, repertoire skewing can show
up in a limited way, which may be the case here with the prefer-
ential use of a very small number of VH and JH gene segments by
CD138+ splenic B-1a cells.
Prominent among variably expressed VH gene segments is VH3,
which was found to be increased in NZM2410 anti-nuclear anti-
bodies as compared to antibodies that did not bind nuclear com-
ponents (30). This might suggest that CD138+ splenic B-1a cells
predominantly generate anti-microbial as opposed to self-reactive
antibodies; however, in NZM2410 mice VH5 is also increased in
anti-nuclear antibodies (30) and among splenic B-1a cells VH5 is
utilized more frequently by CD138+ B-1a cells as compared to
CD138− B-1a cells, although this difference did not reach statisti-
cal significance. Thus, there is no clear evidence that CD138+ B-1a
cell Ig skews more toward or away from autoreactivity.
Both CD138+ and CD138− splenic B-1a cell Ig sequences con-
tained more N-addition than peritoneal B-1a cells’ Ig sequences
(and less N-addition than splenic B-2 cell Ig sequences), suggesting
that the splenic B-1a pool differs from B-1a cells located else-
where as well as from B-2 cells that share the splenic environment.
Moreover, among splenic B-1a cell Ig, CD138+ B-1a sequences
contained more N-addition than CD138− sequences. It has been
shown the natural IgM produced by B-1a cells is essential for
early protection against bacterial and viral infections and that N-
addition plays a substantial role in determining antibody diversity
and effectiveness (10, 11, 13, 15). For example, the prototypi-
cal B-1a anti-phosphorylcholine (PC) antibody, T15, represents
a germline sequence and has no N-addition (31). T15 has been
shown to be protective against Streptococcus pneumoniae infection
(31). The relationship between N-addition and antibody func-
tion is illustrated by the finding that after vaccination with heat
killed pneumococci, mice that overexpress TdT generated an anti-
PC response, but the anti-PC antibodies in this situation were
not protective against S. pneumoniae infection (32). These find-
ings highlight the importance of N-addition, which varies among
antibodies spontaneously secreted by CD138+ splenic B-1a cells,
CD138− B-1a splenic B-1a cells, and peritoneal B-1a cells, in
determining protection by natural antibody.
Circulating natural antibody is primarily generated by splenic
B-1a cells, which differ in many characteristics from peritoneal
B-1a cells (17–19). Among splenic B-1a cells, CD138+ B-1a cells
differ from CD138− B-1a cells in the frequency of secreting cells,
the amount of antibody secreted, and the repertoire of antibody
expressed. The combination of skewing with respect to VH and JH
gene segments, and degree of N-region addition, suggests that the
CD138+ B-1a cell pool does not result from randomly triggered
differentiation events applied to all splenic B-1a cells or all peri-
toneal B-1a cells, but rather results from a selective process whose
origin remains unclear.
This raises the question of how the distinct splenic B-1a pop-
ulations come about, and whether this represents selection from
a pre-existing population or contribution from a new or differ-
ent source. Previous work suggests several potential mechanisms.
Peritoneal B-1a cells may migrate to the spleen following antigen-
specific (or non-specific) activation (21–23, 33, 34). Herzenberg
and colleagues have shown that these B-1a cells may become
antibody secreting cells and/or return to the peritoneal cavity as
memory B cells (21–23, 33, 34). In addition, we and others have
suggested that the pool of B-1a cells changes with age, as fetal liver-
derived B-1a cells are slowly replaced by bone marrow-derived
B-1a cells in the adult expressing antibody with increased levels of
N-addition (8, 35, 36), and the latter could preferentially give rise
to splenic B-1a cells. A further possibility relates to the report of B-
1 progenitor cells in the spleen that might give rise to mature B-1a
cells in situ (37, 38). In fact, a combination of these mechanisms
may be at play, whereby the fetal liver B-1a pool in the peritoneal
cavity is replaced by bone marrow-derived B-1a emigrants over
time, which then become activated and migrate to the spleen in
a selective fashion. It will be of interest to determine whether the
N-addition and other characteristics of CD138+ B-1a cells change
with advancing age. In sum, CD138+ splenic B-1a cells constitute
a distinct B-1a cell population that appears to play a substantial
role in generation of natural antibody.
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